23 Participants Needed

Danuglipron for Obesity

PC
Overseen ByPfizer CT.gov Call Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese: * how the study medicine, danuglipron, is taken up into the blood * about the safety and tolerability of danuglipron The total number of weeks of the study is about 15 (about 4 months).

Research Team

PC

Pfizer CT.gov Call Center

Principal Investigator

Pfizer

Eligibility Criteria

This trial is for adults who are generally healthy but have overweight or obesity issues. Participants will be involved in the study for approximately 15 weeks, which is about 4 months.

Inclusion Criteria

Body mass index (BMI) of ≥25.0-45.4 kg/m2; and a total body weight >50 kg (110 lb)

Exclusion Criteria

I have no significant medical conditions or abnormal lab results.
Known intolerance/hypersensitivity to a GLP-1R agonist
I have a condition that might affect how my body absorbs medication.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive multiple doses of danuglipron to evaluate pharmacokinetics, safety, and tolerability

11-13 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

2-4 weeks

Treatment Details

Interventions

  • Danuglipron
Trial Overview The study focuses on understanding how danuglipron, a medication under investigation, behaves in the bloodstream after multiple doses over several days and assessing its safety and tolerability in participants.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Single ArmExperimental Treatment1 Intervention
Participants will receive multiple doses of danuglipron

Find a Clinic Near You

Who Is Running the Clinical Trial?

Pfizer

Lead Sponsor

Trials
4,712
Recruited
50,980,000+
Known For
Vaccine Innovations
Top Products
Viagra, Zoloft, Lipitor, Prevnar 13

Albert Bourla

Pfizer

Chief Executive Officer since 2019

PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki

Patrizia Cavazzoni profile image

Patrizia Cavazzoni

Pfizer

Chief Medical Officer

MD from McGill University

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security